Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.

doi:10.1016/j.ygyno.2024.02.029

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.

Gynecologic oncology - 1 Apr 2024

Passarelli Anna, Carbone Vittoria, Pignata Sandro, Mazzeo Roberta, Lorusso Domenica, Scambia Giovanni, Canova Stefania, Di Palma Teresa, Tasca Giulia, Mantiero Mara, Naglieri Emanuele, Andreetta Claudia, Rauso Martina, Brunetti Anna Elisabetta, Laera Letizia, Abeni Chiara, Scandurra Giuseppa, Gambaro Anna Rita, Pastore Alessia, Bengala Carmelo, Gunnellini Marco, Farolfi Alberto, Spinello Maurizio, Bartoletti Michele

Abstract excerpt

OBJECTIVE: Recurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options are urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential treatment target. Alpelisib is an α-specific PI3K inhibitor approved in PIK3CA-mutated advanced breast cancer. We report outcomes from a large series of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Class I Phosphatidylinositol 3-Kinases

Share to Endometrial Neoplasms

Share to Genital Neoplasms, Female

Share to Ovarian Neoplasms

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Thiazoles

Source

Open in PubMed

Identifiers

PMID: 38518529
DOI: 10.1016/j.ygyno.2024.02.029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.PMID 38518529Read ↗

The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancerSemantic proximity Read ↗

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.Semantic proximity Read ↗

Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.Semantic proximity Read ↗

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.Semantic proximity Read ↗

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.Semantic proximity Read ↗

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read ↗

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH TrialSemantic proximity Read ↗

PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report.Semantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Semantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.